<DOC>
	<DOCNO>NCT01129011</DOCNO>
	<brief_summary>This study use randomize , double-blind , control design demonstrate PN400 ( esomeprazole naproxen ) effective reduce occurrence gastroduodenal ulcer , dyspepsia , heartburn subject risk develop NSAID-associated gastric ulcer compare naproxen alone .</brief_summary>
	<brief_title>Evaluating PN 400 ( VIMOVO ) Reducing Gastric Ulcers Compared Non-steroidal Antiinflammatory Drug ( NSAID ) Naproxen</brief_title>
	<detailed_description>Objectives : Primary : To demonstrate PN400 effective reducing risk gastric ulcer subject risk develop NSAID-associated gastric ulcer . Secondary : - To determine PN400 effective reducing risk duodenal ulcer subject risk develop NSAID-associated ulcer - To compare upper gastrointestinal symptom subject treat PN400 versus naproxen measure score Severity Dyspepsia Assessment ( SODA ) instrument Overall Treatment Evaluation - Dyspepsia ( OTE-DP ) - To compare heartburn symptom subject treat PN400 versus naproxen - To evaluate safety tolerability PN400 naproxen</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Stomach Ulcer</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Anti-Inflammatory Agents , Non-Steroidal</mesh_term>
	<criteria>Inclusion Criteria A subject eligible inclusion study follow criterion apply : 1 . Male nonpregnant , nonbreastfeeding female subject history osteoarthritis , rheumatoid arthritis , ankylose spondylitis medical condition expect require daily NSAID therapy least 6 month , 1849 year age history document , uncomplicated gastric duodenal ulcer ( mucosal break least 3 mm diameter depth , without concurrent bleeding , clot perforation ) within past 5 year OR , 50 year age old ( These subject require history document , uncomplicated gastric duodenal ulcer within past 5 year . ) 2 . Female subject eligible participation study nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) ; childbearing potential , negative pregnancy test Screening , least 1 follow apply agreed subject : Female sterilization sterilization male partner Hormonal contraception oral route , implant , injectable , vaginal ring Any intrauterine device publish data show low expected failure rate &lt; 1 % per year Double barrier method ( 2 physical barrier 1 physical barrier plus spermicide ) Any method publish data show low expected failure rate &lt; 1 % per year 3 . Each subject require understand comply study procedure require subject able willing provide write informed consent prior study procedure perform . Exclusion Criteria A subject eligible study 1 follow criterion apply : 1 . History hypersensitivity esomeprazole another PPI 2 . History allergic reaction intolerance NSAID ( include aspirin ) and/or history NSAIDinduced symptom asthma , rhinitis , and/or nasal polyp 3 . Participation study investigational treatment 4 week Screening 4 . Presence uncontrolled acute chronic medical illness , e.g. , GI disorder , hypertension , diabetes , thyroid disorder , depression and/or infection would endanger subject participate study 5 . GI disorder surgery lead impaired drug absorption 6 . Evidence uncontrolled , unstable cardio cerebrovascular disorder , investigator 's opinion would endanger subject participate study 7 . Schizophrenia bipolar disorder 8 . Use excluded concomitant medication ( see Section 9.4.8 ) 9 . A recent history ( past 3 month ) suggestive alcohol drug abuse dependence , include overuse/abuse narcotics management pain 10 . Serious blood coagulation disorder , include use systemic anticoagulant 11 . Positive test result H. pylorus Screening 12 . Screening endoscopy show gastric duodenal ulcer least 3 mm diameter depth 13 . Screening laboratory alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) value &gt; 2 time upper limit normal 14 . Estimated creatinine clearance &lt; 30 ml/min 15 . Other note specifically , screen laboratory value clinically significant investigator 's opinion would endanger subject participate study 16 . History malignancy , treat untreated , within past 5 year , exception successfully treat basal cell squamous cell carcinoma skin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>NSAID</keyword>
	<keyword>gastric ulcer</keyword>
	<keyword>Vimovo</keyword>
	<keyword>Esomeprazole</keyword>
	<keyword>Naproxen</keyword>
</DOC>